Experience

Physiomics plc

• United Kingdom
• Biotechnology Research
• 1 - 100 Employee

• Senior PKPD Modeller

  • May 2022 - Present

  Mathematical models to support the development of drug treatment regimens and personalised medicine solutions. Mathematical models to support the development of drug treatment regimens and personalised medicine solutions.



Applied Pharma Modeling & Statistics Ltd.

• Director

  • Mar 2022 - Present

  Applied Pharma Modeling & Statistics Ltd. (ApPharMS) is a privately-owned service provider aiming to provide timely decision-making results that have a fundamental impact on drug development programs:* design and implementation of PKPD-model informed drug development strategies across various therapeutic areas.* statistical support at the preclinical, translational, and clinical stages. * other (custom-made/bespoke) statistical and modelling services. Applied Pharma Modeling & Statistics Ltd. (ApPharMS) is a privately-owned service provider aiming to provide timely decision-making results that have a fundamental impact on drug development programs:* design and implementation of PKPD-model informed drug development strategies across various therapeutic areas.* statistical support at the preclinical, translational, and clinical stages. * other (custom-made/bespoke) statistical and modelling services.



F-star, an invoX company

• United Kingdom
• Biotechnology
• 1 - 100 Employee

• Senior Scientist: PKPD modelling and statistics

  • Jan 2019 - Feb 2022

  Highly collaborative effort to support the development of F-star’s capabilities in modelling and statistics with application to the following areas:• PKPD translational modelling of preclinical in vitro and in vivo data to enable first in human dose selection and target therapeutic dose estimation: - performed PKPD modelling of monkey, mouse, and clinicial (phase I) data, allometric scaling to humans, and simulations of clinical PK for three different lead products (bispecific antibodies). I performed the data analysis and model building and fitting and prepared written technical reports. They were part of two successful IND applications for drugs currently scheduled to be tested in the clinic. - Managed external consultants (PKPD modelling groups) to outsource some of F-star's PKPD modelling programs as needed. Coordinated with internal discovery and development biologists, as well as with external consultants, to inform experimental in vitro and in vivo approaches to provide data for modelling and simulation in diverse areas.As the company’s sole statistician, I provided expert support to project teams to design, execute and interpret quantitative pharmacology studies, by conducting statistical design of experiments including power studies, and implementing processes for statistical analysis of data. Provided biostatistical leadership, training and support to all areas of the R&D organisation as needed.



F-star, an invoX company

• United Kingdom
• Biotechnology
• 1 - 100 Employee

• Scientist: Statistics and PKPD modeling

  • Aug 2017 - Aug 2018

  Highly collaborative effort to support the development of F-star’s capabilities in modelling and statistics with application to the following areas:• PKPD translational modelling of preclinical in vitro and in vivo data to enable first in human dose selection and target therapeutic dose estimation: - performed population PK modelling of monkey data, allometric scaling to humans, and simulations of clinical PK for three different lead products (bispecific antibodies). I performed the data analysis and model building and fitting in its entirety and prepared written technical reports. They were part of a successful IND application for a drug currently tested in the clinic and two pre-IND applications for two other drugs currently in the preclinical stage.• Preclinical (mouse) PK: lead/target selection; study design; and sample size calculations (power studies).As the company’s sole statistician, I additionally played a central role providing statistics consultancy, conducting statistical design of experiments including power studies, and implementing processes for statistical analysis of data. I developed and implemented comprehensive methods in Stata for mixed model analysis of tumor-growth inhibition data in mice and sample size calculations using power studies, as well as for survival analysis using the log-rank test and Cox modeling. Provided biostatistical leadership, training and support to all areas of the R&D organisation as needed.



NIOX®

• United Kingdom
• Medical Device
• 1 - 100 Employee

• Scientist: Statistics & Mathematical Modeling

  • Oct 2014 - Apr 2017

  Collaborative effort to support the Circassia business by providing statistical analysis of product performance data to a level suitable for inclusion in regulatory submissions:• Pharmacokinetic modeling of drug absorption via competing lung/stomach pathways using in vitro lung models• Developed novel statistical tools for and performed analysis of in vivo biochemical data to confirm immune response to allergy drug treatment• Performed statistical analysis of in vitro data for test vs. reference products (bioequivalence)• Provided written reports suitable for inclusion within regulatory submissions.• Internal statistical consultancy



Elance-oDesk

• Technology, Information and Internet
• 100 - 200 Employee

• Statistics/Mathematical Modeling Consultant and Scientific Writer

  • Apr 2012 - Oct 2014

  Provided statistical consultancy or general science input to a range of clients and projects. Work performed included mathematical modeling, statistical analyses, MATLAB, R, and Stata programming, science writing, and editing and proofreading of technical writing. Provided statistical consultancy or general science input to a range of clients and projects. Work performed included mathematical modeling, statistical analyses, MATLAB, R, and Stata programming, science writing, and editing and proofreading of technical writing.



DTU - Technical University of Denmark

• Denmark
• Research Services
• 700 & Above Employee

• Ph.D.

  • Sep 2008 - Mar 2012

  Collaborative effort to expand the theoretical base for mathematical modeling of cell motility on isotropic and anisotropic substrates. Found correlations between motility patterns and substrate nanotopology.• Developed, implemented, and tested a complete MATLAB cell tracking package • Developed, implemented, and tested new methodologies for modeling cell motility• Optimization of parameter fitting from experimental data• Used the computational and mathematical tools thus developed to model and parametrize cell motility on a range of flat and nanostructured; isotropic and anisotropic surfaces.



Stanford University

• United States
• Higher Education
• 700 & Above Employee

• M.Sc.

  • Sep 2004 - Jun 2008

  In collaboration with the research team, employed experimental biophysical (optical trapping) and biochemical techniques to characterize the interaction between myosin VI and its cargo protein, Miranda. Found supportive evidence towards a proposed model for cargo-induced activation of myosin VI by cargo binding-dependent disruption of the myosin head-tail interaction. In collaboration with the research team, employed experimental biophysical (optical trapping) and biochemical techniques to characterize the interaction between myosin VI and its cargo protein, Miranda. Found supportive evidence towards a proposed model for cargo-induced activation of myosin VI by cargo binding-dependent disruption of the myosin head-tail interaction.



Cornell University

• United States
• Higher Education
• 700 & Above Employee

• Research assistant

  • Jan 2001 - May 2004

  Collaborative effort to solve several crystal structures, some diffracting to atomic resolution. Compared intra- vs. intermolecular electron transfer rates in protein crystals. Found correlations between the kinetics and the interface between donor-acceptor sites, known from my crystallography studies. Collaborative effort to solve several crystal structures, some diffracting to atomic resolution. Compared intra- vs. intermolecular electron transfer rates in protein crystals. Found correlations between the kinetics and the interface between donor-acceptor sites, known from my crystallography studies.